Drug intelligence / Profile preview

AMG 598 + liraglutide

Development stage: Unknown
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides, Small Molecules
Administration: Subcutaneous

Overview

AMG 598 + liraglutide is a combination therapy under early-stage clinical investigation for obesity. AMG 598 is a human monoclonal antibody with immunomodulatory properties, developed by Amgen, while liraglutide is a glucagon-like peptide 1 receptor agonist, already approved for weight management. This combination is being evaluated for safety, tolerability, pharmacokinetics, and pharmacodynamics, with the aim to potentiate weight loss by leveraging both immunomodulation and incretin-based therapy[1][2][7].

Other names: AMG-598AMG598AMG 598

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on AMG 598 + liraglutide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMG 598 + liraglutide.

Explore the full profile